Patient Characteristics
Characteristics | Safety set | Immunologic set |
---|---|---|
n = 12 | n = 11 | |
Age in years, median (range) | 48 (31, 62) | 49 (31, 62) |
n (%) | n (%) | |
Gender | ||
Female | 12 (100%) | 11 (100%) |
Race | ||
Caucasian | 12 (100%) | 11 (100%) |
Ethnicity | ||
Non-Hispanic | 12 (100%) | 11 (100%) |
Menopausal Status | ||
Post-menopausal | 8 (67%) | 7 (64%) |
Pre-menopausal | 4 (33%) | 4 (33%) |
Pathologic Type | ||
Ductal | 11 (92%) | 11 (100%) |
Unknown | 1 (8%) | |
Histologic Grade | ||
Grade II | 3 (25%) | 3 (27%) |
Grade III | 8 (67%) | 7 (64%) |
Unknown | 1 (8%) | 1 (9%) |
Stage | ||
II | 3 (25%) | 3 (27%) |
III | 9 (75%) | 8 (73%) |
ER Status | ||
Negative | 5 (42%) | 5 (45%) |
Positive | 7 (58%) | 6 (55%) |
PR Status | ||
Negative | 6 (50%) | 6 (55%) |
Positive | 6 (50%) | 5 (45%) |
Her 2/Neu Status | ||
Negative | 6 (50%) | 5 (45%) |
Positive | 5 (42%) | 5 (45%) |
Unknown | 1 (8%) | 1 (9%) |
On Hormonal Therapy | ||
No | 6 (50%) | 5 (45%) |
Yes | 6 (50%) | 6 (55%) |
Type | ||
Arimidex | 3 | 3 |
Tamoxifen | 3 | 3 |
HLA type (may be multiple) | ||
A1 | 7 (58%) | 7 (64%) |
A2 | 5 (42%) | 4 (36%) |
A3 | 6 (50%) | 6 (55%) |